Noam Frey, MD, MBA, is our SVP, Global Medical Affairs. Prior to joining Summit, Dr. Frey served as VP Medical Affairs at Amryt Pharma plc, where he played a pivotal role in leading the company’s medical teams in bringing therapeutic solutions to patients suffering from ultra-rare diseases across North and Latin America. Before his tenure at Amryt, Dr. Frey held an executive leadership position at Jazz Pharmaceuticals plc, managing both the Medical Affairs and Pharmacovigilance departments.

Dr. Frey’s illustrious career also includes his role as Vice President of Medical Affairs at InterMune,Inc. and his global leadership in Medical Affairs for Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) Alzheimer’s Immunotherapy program.

Throughout his career in the biopharmaceutical industry, Dr. Frey has demonstrated exceptional leadership, spearheading the establishment of several purpose-driven medical affairs departments, with the goal of bringing new therapies to patients suffering from orphan diseases; he was a key contributor to several drug launches, including tadalafil, pirfenidone, defibrotide sodium, and liposomal cytarabine-daunorubicin.

Dr. Frey’s academic background includes a Bachelor of Medical Science and Medical Doctor degrees from Tel Aviv University School of Medicine, as well as an MBA from the University of Washington. His commitment to the field extends beyond his professional endeavors, as he serves as a member of the Scientific Board of Advisors for H1, Inc., a global healthcare data technology company and contributed his expertise to Unlock, a Silicon Valley-based consultancy consortium dedicated to supporting Israeli health and biopharmaceutical startup companies.